Carcinoid Abstract #188

Introduction: There is a serious need to develop a clear framework based on multidisciplinary team practice, in order to facilitate early detection and management of carcinoid.
Aim(s): To examine NPs' knowledge of carcinoid and its relationship with demographic characteristics, the number of patients with carcinoid.
Materials and methods: Background data were obtained using a demographic data collection tool. Twenty multiple choice questions assessed NPs' knowledge of carcinoid. Data were collected over a two-day period at the National Clinical Conference, organized by the AANP. A convenience sample of 90 NPs attending the conference was selected, with response rate 100%.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Assistant Prof Maria Derylo

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1331 The Symptoms Experienced by Small Bowel and Pancreatic NET Patients Prior to Diagnosis Do Not Meet the Criteria for a Functional Diarrhoea (IBS-D) Diagnosis
Introduction: Patients with neuroendocrine tumours (NETs) complain of symptoms that may be mistaken for irritable bowel syndrome (IBS). There is no clear data if these symptoms overlap with those of IBS or if differentiating symptoms co-exist.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Ron Basuroy
#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
Authors: Williams M, Reid K, Ng S, Benny A, ...
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
#2058 On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs): RECOSY Study Design
Introduction: NET pts have high rates of mortality and morbidity, as wells as decreased health-related quality of life (HRQoL) due to CS. Though there is little research on the economic impact of CS, recent studies show that some symptoms, i.e. diarrhoea, are associated with higher healthcare expenditure and use of resources.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Guillermo de La Cruz
#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Philippe Ruszniewski
Keywords: PRO